Fever News and Research

RSS

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Survey: Pharmacists top OTC product picks in more than 77 total categories

The 2010 Pharmacy Today Over-the-Counter Product Survey, conducted by the American Pharmacists Association, reveals pharmacists believe that 81% of consumers purchase the over-the-counter product that was recommended by their pharmacist, 92% of pharmacists walk a patient to the OTC section to assist with a product selection and the average patient consult takes only three minutes of the patient's time.

26 Apr 2011

GSK receives FDA approval for Lamictal XR to treat partial seizures

GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.

26 Apr 2011

Scientists develop new low cost test for acute pancreatitis

A new low cost test for acute pancreatitis that gets results much faster than existing tests has been developed by scientists at The University of Texas at Austin.

26 Apr 2011

Viewpoints: Sebelius on medical mistakes; Stockman on solving deficit; Fox on Medicare's political history

A recent study found that as many as one out of three hospital patients is harmed by his or her care. And the Institute of Medicine estimates that as many as 100,000 Americans die each year from preventable medical errors in hospitals. That's about the number of annual deaths caused by auto accidents, AIDS, and breast cancer combined.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Ahead of Immunization Week, WHO calls for countries to come together to control measles outbreak in Europe

WHO is urging countries in Europe to join together to help control the measles outbreak that has grown to more than 6,500 cases in 33 countries and the potential for worsening outbreaks "in the days ahead as people travel during the Easter holidays," U.N. News Centre reports.

25 Apr 2011

Sanofi Pasteur receives FDA approval for Menactra to prevent meningococcal disease

The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.

24 Apr 2011

'Iceman' influences autonomic nervous system and immune response

At the Radboud University Nijmegen Medical Centre, professor of experimental intensive care medicine dr. Peter Pickkers and his team have performed research on "Iceman" Wim Hof. Hof claims that he can influence his autonomic nervous system and immune response through concentration and meditation.

22 Apr 2011

Researchers discover new compound to fight against shingles

Researchers at the University of Georgia and Yale University have discovered a compound with the potential to be more effective than existing agents in treating the very painful blisters known as shingles-a condition that affects up to 30 percent of Americans, mostly elderly, and for which no specific treatment exists.

22 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

$2.3 million of malaria medicines stolen

According to the Global Fund to Fight AIDS, Tuberculosis and Malaria, malaria medications valued at almost $2.3 million may have been stolen from government-run distribution centers in Africa and other locations.

20 Apr 2011

IBD patients at greater risk of death if infected with Clostridium difficile

Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness.

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

Cumberland acquires Vanderbilt's ifetroban rights

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.

19 Apr 2011

Groundbreaking news on Dengue

Daily temperature fluctuations, not just high temperatures, play a significant role in the transmission of dengue, a deadly mosquito-borne disease that strikes millions of people in tropical and subtropical countries, according to ground-breaking research led by French, Thailand and U.S. scientists and conceived by medical entomologist Thomas Scott of the University of California, Davis.

18 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

Measles alert issued in Tasmania

Tasmanian health authorities have issued an alert over a measles case. They issued a statement revealing that a woman who travelled to Devonport on the Spirit of Tasmania on Monday has been diagnosed with the infectious disease. She was one of four people to contract measles while on board an Air Asia flight from Kuala Lumpur to Melbourne.

17 Apr 2011